Insider Selling: XOMA Co. (NASDAQ:XOMA) CEO Sells 21,881 Shares of Stock

XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at $1,047,621.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

XOMA Trading Down 5.0 %

Shares of XOMA stock traded down $1.55 during trading hours on Wednesday, reaching $29.71. The company had a trading volume of 116,262 shares, compared to its average volume of 21,623. The company has a 50 day moving average of $28.60 and a 200 day moving average of $26.84. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The firm has a market cap of $349.98 million, a price-to-earnings ratio of -8.54 and a beta of 0.90. XOMA Co. has a 1-year low of $14.33 and a 1-year high of $33.78.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $11.09 million for the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. On average, equities research analysts anticipate that XOMA Co. will post -0.79 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on XOMA shares. HC Wainwright restated a “buy” rating and issued a $117.00 price objective on shares of XOMA in a research report on Wednesday, October 23rd. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

Hedge Funds Weigh In On XOMA

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of XOMA during the first quarter valued at about $212,000. Rhumbline Advisers boosted its stake in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares in the last quarter. Ellsworth Advisors LLC bought a new position in XOMA during the third quarter valued at approximately $516,000. Finally, Bank of New York Mellon Corp increased its holdings in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.